40 Hz Visual Stimulation as an Intervention in Schizophrenia
Launched by TECHNICAL UNIVERSITY OF MUNICH · Mar 26, 2025
Trial Information
Current as of September 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people with schizophrenia, particularly those who experience negative symptoms like difficulty thinking clearly or feeling low. Researchers want to see if a type of brain stimulation using 40 Hz visual patterns can improve these symptoms. The study will involve at least ten patients diagnosed with schizophrenia or schizoaffective disorder who have these symptoms. Participants will receive this visual stimulation for one hour a day over five days, during which they will be encouraged to relax or fall asleep. There will also be a separate group of patients who will continue their usual treatment without the stimulation.
To be eligible for the trial, participants must be at least 18 years old and have a medical diagnosis of schizophrenia or schizoaffective disorder. However, those with a history of seizures, acute suicidal thoughts, certain other mental health conditions, or specific vision problems will not be able to participate. Before and after the stimulation sessions, researchers will assess participants' brain activity and their cognitive and emotional well-being through various tests. The findings from this study could help determine if this type of visual stimulation is a safe and helpful addition to current treatments for schizophrenia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Medical diagnosis of schizophrenia (F20) or schizoaffective disorder (F25)
- Exclusion Criteria:
- • Age \< 18 years
- • Any history of seizures
- • Acute suicidality assessed with the Columbia-Suicide Severity Rating Scale (C-SSRS; Brent et al., 2008)
- • Any other relevant axis 1 disorder
- • Red-green colour blindness or current ocular disease
- • Alcohol, cannabis, or illicit drug addiction within the last 3 months
About Technical University Of Munich
The Technical University of Munich (TUM) is a leading research institution in Germany, renowned for its commitment to excellence in education, innovation, and technology transfer. With a strong emphasis on interdisciplinary collaboration, TUM fosters advancements in various fields, including medicine and life sciences. The university actively engages in clinical research, aiming to translate scientific discoveries into practical applications that improve patient outcomes. Through its state-of-the-art facilities and a network of partnerships with hospitals and industry, TUM is dedicated to conducting rigorous clinical trials that adhere to the highest ethical standards and contribute significantly to the advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Bavaria, Germany
Patients applied
Trial Officials
Ulrike Vogelmann, MD
Principal Investigator
TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported